Article
The Role of c-Met as a Biomarker and Player in Innate and Acquired Resistance in Non-Small-Cell Lung Cancer: Two New Mutations Warrant Further Studies.
Molecules (Basel, Switzerland) - 4 Dec 2019
Van Der Steen Nele, Zwaenepoel Karen, Mazzaschi Giulia, A Luirink Rosa, P Geerke Daan, Op de Beeck Ken, Hermans Christophe, Tiseo Marcello, Van Schil Paul, Lardon Filip, Germonpré Paul, Rolfo Christian, Giovannetti Elisa, J Peters Godefridus, Pauwels Patrick
Abstract excerpt
The c-Met receptor is a therapeutically actionable target in non-small-cell lung cancer (NSCLC), with one approved drug and several agents in development. Most suitable biomarkers for patient selection include c-Met amplification and exon-14 skipping. Our retrospective study focused on the frequency of different c-Met aberrations (overexpression, amplification and mutations) in 153 primary, therapy-naïve...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.